SCHEMBL6831374

SCHEMBL6831374

CCCCCCCCCCS(=O)(=O)N1CCCCC1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 5/20 0.54
ALDH1A1 P00352 3/20 0.43
HTT P42858 1/20 0.43
MMP8 P22894 3/20 0.42
MMP3 P08254 1/20 0.42
MMP1 P03956 1/20 0.38
MMP7 P09237 1/20 0.38
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6831371 1.00 FKBP1A (0.54) FKBP1AALDH1A1HTTMMP8MMP3
Hydroxyamine SCHEMBL5894442 0.96 FKBP1A (0.50) FKBP1AALDH1A1HTTMMP8MMP3
SCHEMBL6830973 0.95 FKBP1A (0.58) FKBP1AMMP8MMP3MMP1MMP7
SCHEMBL6830972 0.95 FKBP1A (0.58) FKBP1AMMP8MMP3MMP1MMP7
SCHEMBL3256301 0.94 FKBP1A (0.56) FKBP1AALDH1A1HTTMMP8MMP3
SCHEMBL3256303 0.94 FKBP1A (0.56) FKBP1AALDH1A1HTTMMP8MMP3
SCHEMBL10815653 0.89 FKBP1A (0.48) FKBP1AALDH1A1HTTMMP8MMP3
SCHEMBL26212073 0.89 FKBP1A (0.51) FKBP1AALDH1A1HTTMMP8MMP1
SCHEMBL9103345 0.83 FKBP1A (0.47) FKBP1AALDH1A1HTTMMP8MMP1
SCHEMBL9103351 0.83 FKBP1A (0.47) FKBP1AALDH1A1HTTMMP8MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770656-B2 NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2004-08-03 US claimed
US-20030216427-A1 Amine derivatives for the treatment of apoptosis MERCK SERONO SA (CH) 2003-11-20 US claimed
EP-1263730-A1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS Applied Research Systems ARS Holding N.V. (AN) 2002-12-11 EP claimed
WO-2001060798-A1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-08-23 WO claimed
US-6770656-B2 NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2004-08-03 US disclosed
US-20030216427-A1 Amine derivatives for the treatment of apoptosis MERCK SERONO SA (CH) 2003-11-20 US disclosed
EP-1263730-A1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS Applied Research Systems ARS Holding N.V. (AN) 2002-12-11 EP disclosed
WO-2001060798-A1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216427-A1 Amine derivatives for the treatment of apoptosis BAD, BAX, BCL2 FKBP1A 3730/4885ALDH1A1 1684/4885HTT 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.